U-M's retinal disease drug developer has secured $46.9m of series B capital from investors including Mints.

ONL Therapeutics, a US-based retinal diseases therapy developer spun out of University of Michigan, has closed a $46.9m series B round featuring the institution’s Michigan Investment in New Technology Startups (Mints) programme. Western Michigan University’s Biosciences Research & Commercialization Center also took part in the round. The round was led by venture capital firm Bios…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.